Capricor to Present at Third Annual CELLutions SUMMIT 2008

Los Angeles, Calif. – July 5, 2008. Capricor Inc. (www.capricor.com), announced that Dr. Rachel Smith, Project Leader Regenerative Medicine, will present the company's technology to the business Five@Five forum at the Cambridge Healthtech Institute's Third Annual CELLutions SUMMIT, to be held on August 11-13, 2008 at the Boston Marriott Cambridge Hotel.

Capricor's forum presentation, entitled *Capricor Stem Cells: Heart to Heart,* highlights data advances made by Capricor in the development of its CDC or Cardiosphere-derived stem cell technology.

"With excellent large animal data that is currently under review for publication, our program is poised to begin human clinical trials," said Dr. Smith. "Capricor has rapidly progressed through preclinical testing on a minimum of seed funding, and we are well positioned with an FDA investigational new drug (IND) application planned for the coming months," said Oliver Foellmer, President and CEO.

Capricor is currently in the process of raising a second round of financing, which is targeted to support the company's human clinical trials.

Cells are potential solutions! Cambridge Healthtech Institute's Third Annual CELLutions SUMMIT (www.healthtech.com/cellutions/overview.aspx) is uniquely designed to explore the evolving field of next-generation cells, engineered 3D cellular models, and therapeutic cellular-in-human use. Scientific technological progress brings fundamental understanding and provides the foundation for rapid advances toward the clinic.

Capricor Inc., located in Los Angeles, California, is a leading biotechnology company that specializes in discovering, developing, and commercializing biotherapeutics for the treatment of heart diseases. Capricor's mission is to revolutionize the treatment of cardiac disease by translating novel stem cell science into therapeutics that halt and reverse the disease process for patient's, their families, and society in general.